NOVARTIS

Sponsor

Gyroscope Therapeutics Limited

Generic Drug Name

GT005 / PPY988

Trial Indication(s)

Macular Atrophy due to Age-related Macular Degeneration

Protocol Number

GT005-01 / CPPY988A12101

Protocol Title

FOCUS: An open label first in human Phase I/II multicentre study to evaluate the safety, dose response and efficacy of GT005 administered as a single subretinal injection in subjects with Macular Atrophy due to AMD

Clinical Trial Phase

Phase 1/Phase 2

Phase of Drug Development

Phase I / II

Study Start/End Dates

Study Start Date: December 17, 2018 (Actual)
Primary Completion Date: June 25, 2024 (Actual)
Study Completion Date: June 25, 2024 (Actual)

NOVARTIS

Reason for Termination (If applicable)

The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.

Study Design/Methodology

This was an open label first-in-human Phase I/II multicenter study to evaluate the safety, dose response and efficacy of GT005 in participants with Geographic atrophy (GA) due to Age-related macular degeneration (AMD).

The study treatment GT005 consists of an Adeno-associated virus serotype 2 (AAV2) expressing human complement factor I (hCFI). The treatment was administered as a single subretinal administration in one eye - the “study eye”. Both eyes were assessed at the screening visit. If both eyes meet the eligibility criteria, the study eye will be the worse seeing eye, or the eye with the largest geographic atrophy (GA) lesion area for eyes with equivalent visual acuity, unless the participant (in consultation with the surgeon) expresses an alternative preference.

The study was conducted in 4 parts: in Part 1 and Part 2 GT005 was administered subretinally via transvitreal procedure; in Part 3 and 4 GT005 was delivered subretinally via a suprachoroidal cannulation with the Orbit Subretinal delivery system (SDS). The Orbit SDS is a 510(k) cleared device in the US, whereby Parts 3 and 4 were only conducted at US sites. The treatment consisted in 3 dose levels: low dose, 2E10 vector genomes (vg); medium dose, 5E10 vg; and high dose, 2E11 vg.

Part 1 (Cohorts 1 to 3; dose-escalation) enrolled a total of 11 participants, with 3 in Cohort 1, 4 in Cohort 2, and 4 in Cohort 3. There was a minimum of 14 days separation between dosing of the first and second participant of each dose cohort, to assess any acute reactions to surgery and the short-term tolerability to GT005 prior to dosing the remaining participants in each dose cohort. Dose escalation was evaluated by a DSMB and assessed based on the Week 5 data for the first three participants dosed in Cohorts 1 and 2. The Data safety monitoring board (DSMB) reviewed the Week 5 safety data for the first three participants dosed in Cohort 3 prior to dosing in further cohorts.

Part 2 (Cohort 4; dose-expansion) where additional 20 participants were enrolled and treated with one of the 3 doses. On completion of dose-escalation, in Part 1, the DSMB assessed the dose levels to be safe and tolerated, enabling the

continuation of dosing additional participant and Cohorts 4 to further characterize the safety, dose response, and efficacy of GT005.

Part 3 (Cohorts 5 and 6: dose-escalation) enrolled 6 participants, with 3 in each cohort. The Orbit SDS device was used for the administration of the medium dose g in Cohort 5, and high dose in Cohort 6. Part 3 was independent of and was conducted in parallel to Part 2 (Cohort 4). Dose-escalation was evaluated by the DSMB on the Week 5 safety data for the first three participants dosed in Cohort 5.

Part 4 (Cohort 7, dose-expansion) where only the high dose was administered in 19 participants to further characterize the safety, efficacy, and tolerability of GT005 when delivered via the Orbit SDS device.

The study consisted of up to 13 visits over a 5-year period. All participants were assessed for the occurrence of treatment emergent adverse events (AE)s at each visit and underwent visual function and retinal imaging assessments and biological sampling as per the schedule of assessments.

This study was conducted in compliance with Independent ethics committees (IECs) / Institutional review boards (IRBs), informed consent regulations, the Declaration of Helsinki, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines, and the Food and Drug Administration (FDA) guidance.

Centers

13 centers in 2 countries: United Kingdom(6), United States(7)

Objectives:

Primary:

To evaluate the safety of GT005 at 3 doses

Secondary:

To evaluate long-term safety of GT005 at 3 doses

To evaluate the effect of GT005 on anatomical and functional visual outcomes

To evaluate the performance of the Orbit Subretinal Delivery System (Orbit SDS) (United States [US] only)

To evaluate the safety of the Orbit SDS (US only)

Test Product (s), Dose(s), and Mode(s) of Administration

GT005 was administered as a single time subretinal injection into the study eye of participants

at one of three dose levels:

• Low dose: 2E10 AAV2 vg in 100 microlitres

• Medium dose: 5E10 AAV2 vg in 100 microlitres

• High dose: 2E11 AAV2 vg in 100 microlitres

Statistical Methods

The following analysis sets were used in this study:

• The All-Enrolled Set included all participants who had signed informed consent.

• The Safety Analysis Set (SAF) included all participants who have undergone surgery and received GT005. The SAF was used for analysis of safety and laboratory data.

• The Full Analysis Set (FAS) included all participants in SAF who have baseline and at least 1 post-baseline value of Geographic atrophy (GA) area size on Fundus autofluorescence (FAF) in the study eye. The FAS was used for the analysis of efficacy data.

Efficacy analyses were conducted using the FAS by treatment dose and route of administration.

GA area (mm2) change from baseline in the study eye as assessed on FAF was presented in spaghetti plots and in a summary by visit table. It was also summarized in a table and line plots as least-squares means with 95% Confidence interval (CI) by visit using mixed model for repeated measures (MMRM) model with fixed effects for treatment (defined as dose and route of administration), study visit, baseline GA area (mm2), treatment by visit interaction and visit by baseline GA area interaction.

Square root of GA area (mm) change from baseline in the study eye was presented in spaghetti plots and in a summary by visit table. It was also summarized in a table and line plots as least squares means with 95% CI by visit using MMRM model with fixed effects for treatment, study visit, square root of baseline GA area (mm), treatment by visit interaction and visit by square root of baseline GA area (mm) interaction. MMRM analysis was repeated for Complement factor I (CFI) rare variant subgroups and Retinal pigment epithelium (RPE) changes subgroups by replacing in the model treatment with subgroups of interest.

The maximum reading speed (MRS) for each eye was assessed by Minnesota low-vision reading test (MNRead) questionnaire. Reading speed (words per minute) was computed for each of the 19 sentences read using the following formula: 60 × max (0,10 – number of errors)/reading time in seconds. Mean of 3 higher reading speeds were reported as maximum reading speed.

The Visual function questionnaire-25 (VFQ-25) questionnaire sub-scales and composite scores and changes from baseline was calculated and summarized by assessment visits.

Analysis of safety endpoints:

Overall summary was provided for death, Adverse event (AEs), severity of AEs, study treatment-related AE, surgical procedure related AEs, AEs leading to study discontinuation, Serious adverse events (SAEs). All AEs, deaths, and SAEs were listed.

Visual Acuity (Best corrected visual acuity (BCVA) and Low luminance visual acuity (LLVA)): BCVA, LLVA and low-luminance deficit (LLD) scores via the Early treatment for diabetic retinopathy (ETDRS) Chart were summarized as actual and change from baseline values over time (visit) by eye, treatment dose, and route of administration. Plots for mean changes from baseline for BCVA, LLVA and LLD (with 95% CI) over time were presented.

Study Population: Key Inclusion/Exclusion Criteria

Inclusion Criteria:

1. Able and willing to give consent to study participation

2. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye (except if the subject is monocular)

3. Cohorts 1 to 6: GA lesion(s) total size in the study eye must be ≥1.25mm2 and ≤17.5mm2.
Cohort 7: GA lesion(s) total size in the study eye must be ≥1.25mm2
4. GA lesion(s) in the study eye must reside completely within the FAF fundus image
5. Cohorts 1 to 3: BCVA of ≤50 letters (6/36 Snellen acuity equivalent or worse) using ETDRS charts in the study eye
Cohorts 4 to 7: BCVA of ≥24 letters (6/95 and 20/320 Snellen acuity equivalent or better) using ETDRS charts in the study eye
6. Aged ≥55 years
7. Able to attend all study visits and complete the study procedures
8. Women of child-bearing potential need to have a negative urine pregnancy test within two weeks prior to receiving the drug. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilised (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy)

Exclusion Criteria:
1. Have evidence or history of Choroidal Neovascularisation (CNV) in the study eye. Subjects are permitted to have CNV in the fellow eye defined as either:
(a) Non-exudative/sub-clinical fellow eye CNV identified at screening, or
(b) Known history of fellow eye CNV with either ≥2 years since diagnosis or with no active treatment required in 6 months prior to screening
2. Presence of moderate/severe non-proliferative diabetic retinopathy or worse in the study eye
3. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye
4. History of intraocular surgery in the study eye within 12 weeks prior to Screening (Visit 1). Yttrium aluminum garnet capsulotomy is permitted if performed >10 weeks prior to Visit 1
5. Have clinically significant cataract that may require surgery during the study period in the study eye

6. Presence of moderate to severe glaucomatous optic neuropathy in the study eye; uncontrolled IOP despite the use of more than two topical agents; a history of glaucoma-filtering or valve surgery is also excluded
7. Axial myopia of greater than -8 diopters in the study eye
8. Have received any investigational product for the treatment of GA within the past 6 months or 5 half-lives (whichever is longer), other than nutritional supplements such as the Age-Related Eye Disease Study (AREDS) formula
9. Have received a gene or cell therapy at any time
10. Have a contraindication to the specified protocol corticosteroid regimen
11. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant
12. Active malignancy within the past 12 months, except for: Appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) ≥12 months
13. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study
14. Cohorts 5 to 7 only: presence of metallic objects or implanted stimulator devices in or near the head, including cochlear implants, deep brain stimulators, vagus nerve stimulators, and other implanted electrodes or stimulators

Participant Flow Table

Overall Study

	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System	Total
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System	
Started	6	10	15	3	22	56

Completed	6	10	14	3	21	54
Not Completed	0	0	1	0	1	2
Physician Decision	0	0	1	0	0	1
Lost to Follow-up	0	0	0	0	1	1

Baseline Characteristics

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**	**Total**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System	
Number of Participants [units: participants]	6	10	15	3	22	56
Baseline Analysis Population Description						
Age Continuous (units: Years) Analysis Population Type: Participants Mean ± Standard Deviation						
	81.7±8.21	79.0±5.12	80.5±4.02	75.7±4.73	77.3±6.60	78.9±5.93
Sex: Female, Male (units: Participants) Analysis Population Type: Participants Count of Participants (Not Applicable)						
Female	5	6	11	3	14	39

Male	1	4	4	0	8	17
Race (NIH/OMB) (units: Participants) Analysis Population Type: Participants Count of Participants (Not Applicable)						
American Indian or Alaska Native	0	0	0	0	0	0
Asian	0	0	1	0	0	1
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0
Black or African American	0	0	0	0	0	0
White	6	10	14	3	22	55
More than one race	0	0	0	0	0	0
Unknown or Not Reported	0	0	0	0	0	0

Primary Outcome Result(s)

Ocular treatment emergent adverse events by primary system organ class and preferred term for the study eye

Description	An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.
Time Frame	Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Analysis Population Description	Safety Analysis Set - All treated patients

NOVARTIS

	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Ocular treatment emergent adverse events by primary system organ class and preferred term for the study eye (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Subjects with at least one TEAE	3 (50%)	7 (70%)	14 (93.33%)	3 (100%)	21 (95.45%)
Congenital, familial and genetic disorders	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Corneal dystrophy	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
Eye disorders	3 (50%)	6 (60%)	13 (86.67%)	3 (100%)	21 (95.45%)
-Retinal pigmentation	0 (%)	4 (40%)	10 (66.67%)	0 (%)	8 (36.36%)
-Conjunctival haemorrhage	0 (%)	0 (%)	0 (%)	3 (100%)	15 (68.18%)
-Cataract	1 (16.67%)	3 (30%)	7 (46.67%)	0 (%)	2 (9.09%)
-Retinal haemorrhage	0 (%)	2 (20%)	1 (6.67%)	3 (100%)	5 (22.73%)
-Dry eye	1 (16.67%)	2 (20%)	2 (13.33%)	0 (%)	2 (9.09%)
-Anterior chamber cell	0 (%)	0 (%)	1 (6.67%)	1 (33.33%)	3 (13.64%)

-Retinal tear	0 (%)	0 (%)	0 (%)	0 (%)	4 (18.18%)
-Blepharitis	0 (%)	3 (30%)	0 (%)	0 (%)	0 (%)
-Conjunctival hyperaemia	0 (%)	0 (%)	1 (6.67%)	0 (%)	2 (9.09%)
-Neovascular age-related macular degeneration	0 (%)	0 (%)	0 (%)	1 (33.33%)	2 (9.09%)
-Visual field defect	0 (%)	0 (%)	3 (20%)	0 (%)	0 (%)
-Charles Bonnet syndrome	1 (16.67%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Eye pain	0 (%)	0 (%)	1 (6.67%)	0 (%)	1 (4.55%)
-Eyelid ptosis	0 (%)	0 (%)	1 (6.67%)	0 (%)	1 (4.55%)
-Visual acuity reduced	1 (16.67%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Vitreous floaters	0 (%)	0 (%)	1 (6.67%)	1 (33.33%)	0 (%)
-Central vision loss	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Chalazion	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)
-Choroidal haemorrhage	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Choroidal neovascularisation	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Conjunctival deposit	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Corneal oedema	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)

-Dacryostenosis acquired	0 (%)	1 (10%)	0 (%)	0 (%)	0 (%)
-Diplopia	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Eye discharge	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)
-Eye pruritus	0 (%)	1 (10%)	0 (%)	0 (%)	0 (%)
-Eyelid irritation	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)
-Foreign body sensation in eyes	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Glaucoma	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Iridocyclitis	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Keratitis	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)
-Macular hole	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Ocular discomfort	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Ocular hypertension	0 (%)	1 (10%)	0 (%)	0 (%)	0 (%)
-Optic disc haemorrhage	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Periorbital oedema	1 (16.67%)	0 (%)	0 (%)	0 (%)	0 (%)
-Posterior capsule opacification	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Retinal depigmentation	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)

-Vision blurred	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Visual impairment	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
Infections and infestations	0 (%)	3 (30%)	0 (%)	0 (%)	2 (9.09%)
-Conjunctivitis	0 (%)	0 (%)	0 (%)	0 (%)	2 (9.09%)
-Conjunctivitis viral	0 (%)	2 (20%)	0 (%)	0 (%)	0 (%)
-Conjunctivitis bacterial	0 (%)	1 (10%)	0 (%)	0 (%)	0 (%)
Injury, poisoning and procedural complications	0 (%)	0 (%)	4 (26.67%)	0 (%)	3 (13.64%)
-Procedural pain	0 (%)	0 (%)	3 (20%)	0 (%)	1 (4.55%)
-Corneal abrasion	0 (%)	0 (%)	1 (6.67%)	0 (%)	1 (4.55%)
-Post procedural discomfort	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Suture related complication	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
Investigations	0 (%)	0 (%)	1 (6.67%)	1 (33.33%)	1 (4.55%)
-Intraocular pressure increased	0 (%)	0 (%)	1 (6.67%)	1 (33.33%)	1 (4.55%)
Nervous system disorders	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)
-Ophthalmic migraine	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)

Summary of Non-Ocular treatment emergent adverse events

Description	An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.
Time Frame	Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Analysis Population Description	Safety Analysis Set - All treated patients

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Summary of Non-Ocular treatment emergent adverse events (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Number of Participants with at least one TEAE	4 (66.67%)	10 (100%)	14 (93.33%)	3 (100%)	16 (72.73%)

Summary of Ocular Serious Treatment-Emergent Adverse Events in the Study Eye by System Organ Class and Preferred

Description	An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.
Time Frame	Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.

Analysis Population Description	Safety Analysis Set - All treated patients

	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Summary of Ocular Serious Treatment-Emergent Adverse Events in the Study Eye by System Organ Class and Preferred (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Number of Participants with at least one TEAE	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)

Secondary Outcome Result(s)

Best corrected visual acuity (BCVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) letters) in the Study Eye

Description	Best corrected visual acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - All treated patients with a valid measurement without a protocol deviation with impact

NOVARTIS

	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Best corrected visual acuity (BCVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) letters) in the Study Eye (units: ETDRS letters read)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Week 1	39.33 ± 16.145	47.20 ± 16.151	47.20 ± 17.449	62.00 ± 17.436	52.59 ± 15.822
Week 5 (n=6,10,14,3,22)	42.00 ± 20.258	46.90 ± 13.916	45.57 ± 19.747	62.67 ± 19.425	52.14 ± 18.838
Week 8 (n=3,4,6,3,21)	60.33 ± 9.074	55.25 ± 9.674	55.67 ± 12.675	65.33 ± 16.442	52.52 ± 18.101
Week 12 (n=6,10,11,3,22)	44.33 ± 21.153	46.00 ± 15.563	54.73 ± 16.032	66.67 ± 16.166	54.68 ± 17.705
Week 24 (n=6,10,13,3,21)	42.67 ± 24.262	44.60 ± 13.810	48.92 ± 20.056	66.67 ± 19.218	52.76 ± 18.144
Week 36 (n=6,6,15,3,21)	39.00 ± 21.790	53.17 ± 12.983	43.80 ± 20.640	65.00 ± 21.932	52.29 ± 18.078
Week 48 (n=5,9,14,3,21)	40.60 ± 19.204	47.22 ± 13.953	47.86 ± 16.176	64.00 ± 20.518	51.19 ± 19.577
Week 72 (n=3,8,14,3,18)	32.67 ± 20.744	46.63 ± 15.408	46.93 ± 13.658	57.33 ± 16.258	51.72 ± 18.162
Week 96 (n=4,8,14,3,18)	31.00 ± 21.494	44.13 ± 12.484	43.57 ± 18.110	64.67 ± 24.583	51.72 ± 19.393
Week 144 (n=2,6,10,3,2)	26.50 ± 28.991	42.50 ± 9.628	43.90 ± 17.515	64.00 ± 18.520	56.00 ± 2.828
Week 192 (n=2,3,7,0,0)	26.50 ± 19.092	35.33 ± 8.505	36.43 ± 15.404		
Week 240 (n=2,1,2,0,0)	25.50 ± 16.263	28.00	25.50 ± 7.778		

NOVARTIS

Low-Luminance Deficit best corrected visual acuity (BCVA-LLVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) letters) in the Study Eye

Description	Low-Luminance Deficit best corrected visual acuity (BCVA-LLVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - All treated patients with a valid measurement without a protocol deviation with impact

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Low-Luminance Deficit best corrected visual acuity (BCVA-LLVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) letters) in the Study Eye (units: ETDRS letters read)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Week 12 (n=3,9,11,3,22)	40.00 ± 21.517	14.67 ± 17.951	18.91 ± 14.321	28.67 ± 17.214	24.82 ± 16.229
Week 24 (n=6,10,13,3,21)	32.25 ± 29.205	15.80 ± 15.061	17.23 ± 13.893	27.00 ± 20.952	22.52 ± 14.473
Week 36 (n=4,6,15,3,20)	26.75 ± 24.865	21.00 ± 14.656	15.07 ± 15.144	30.00 ± 30.806	20.10 ± 14.242
Week 48 (n=5,9,14,3,21)	19.60 ± 14.415	15.11 ± 13.968	17.36 ± 15.736	31.67 ± 24.194	18.48 ± 13.938
Week 72 (n=3,8,14,3,18)	20.33 ± 14.154	13.13 ± 9.538	15.36 ± 17.095	33.67 ± 25.007	21.22 ± 12.735
Week 96 (n=4,8,14,3,18)	16.25 ± 9.215	8.88 ± 4.643	13.07 ± 15.711	36.00 ± 23.065	21.56 ± 13.984
Week 144 (n=2,6,10,3,2)	5.50 ± 6.364	6.50 ± 4.550	18.80 ± 18.760	39.67 ± 22.679	26.00 ± 26.870

Week 192 (n=2,3,7,0,0)	2.00 ± 1.414	5.00 ± 1.414	13.00 ± 9.220
Week 240 (n=2,1,2,0,0)	7.50 ± 2.121	9.00	5.50 ± 3.536

Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate contour ellipse area (BCEA) 63 Area (deg2)

Description	Macular sensitivity as assessed by mesopic Microperimetry. Mesopic Microperimetry (MP) Bivariate contour ellipse area (BCEA) 63 Area.
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - All treated patients with a valid measurement without a protocol deviation with impact

	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	3	9	14	3	11
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate contour ellipse area (BCEA) 63 Area (deg2) (units: degrees squared (deg2))	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Week 12 (n=2,9,11,1,10)	16.80 ± 5.940	15.64 ± 13.013	7.82 ± 8.232	36.90	5.97 ± 3.726
Week 24 (n=3,9,10,3,11)	16.17 ± 15.970	17.10 ± 17.891	12.13 ± 11.483	14.40 ± 20.809	10.38 ± 11.050
Week 48 (n=2,9,14,2,10)	8.50 ± 3.677	19.41 ± 19.557	11.96 ± 7.939	48.55 ± 50.134	11.34 ± 7.527
Week 72 (n=1,8,13,2,10)	17.80	13.33 ± 6.887	12.10 ± 7.970	27.65 ± 38.254	9.66 ± 6.935
Week 96 (n=2,8,13,1,7)	10.90 ± 2.546	14.65 ± 10.059	10.40 ± 6.389	0.30	6.11 ± 4.171

Week 144 (n=1,5,8,2,0)	12.20	18.80 ± 18.404	13.05 ± 7.505	4.30 ± 5.233
Week 192 (1,2,7,0,0)	38.90	7.70 ± 0.283	13.80 ± 8.565	
Week 240 (1,1,2,0,0)	40.20	11.10	18.85 ± 24.395	

Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate contour ellipse area (BCEA) 95 Area (deg2)

Description	Macular sensitivity as assessed by mesopic Microperimetry. Mesopic Microperimetry (MP) Bivariate contour ellipse area (BCEA) 63 Area.
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - All treated patients with a valid measurement without a protocol deviation with impact

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	3	9	14	3	11
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate contour ellipse area (BCEA) 95 Area (deg2) (units: degrees squared (deg2))	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Week 12 (n=2,9,11,1,10)	50.40 ± 17.819	46.86 ± 39.037	23.43 ± 24.638	110.70	17.81 ± 11.120
Week 24 (n=3,9,10,3,11)	48.37 ± 47.853	51.20 ± 53.652	36.28 ± 34.454	43.23 ± 62.405	31.09 ± 33.157
Week 48 (n=2,9,14,2,10)	25.45 ± 10.960	58.17 ± 58.589	35.79 ± 23.804	145.40 ± 150.331	33.96 ± 22.632
Week 72 (n=1,8,13,2,10)	53.40	39.94 ± 20.603	36.28 ± 23.848	82.90 ± 114.693	28.90 ± 20.743

Week 96 (n=2,8,13,1,7)	32.70 ± 7.495	43.90 ± 30.123	31.15 ± 19.152	0.80	18.30 ± 12.563
Week 144 (n=1,5,8,2,0)	36.60	56.32 ± 55.119	39.13 ± 22.511	12.85 ± 15.768	
Week 192 (1,2,7,0,0)	116.40	23.15 ± 0.778	41.33 ± 25.644		
Week 240 (1,1,2,0,0)	120.40	33.40	56.60 ± 73.115		

Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Mean Sensitivity Decibel (dB)

Description	Macular sensitivity as assessed by mesopic Microperimetry
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - All treated patients with a valid measurement without a protocol deviation with impact

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	3	9	14	3	11
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Mean Sensitivity Decibel (dB) (units: Decibel (dB))	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Week 12 (n=2,9,11,1,10)	14.30 ± 2.121	7.76 ± 5.536	11.92 ± 5.165	0.90	13.51 ± 3.350
Week 24 (n=3,9,10,3,11)	4.20 ± 3.704	7.31 ± 5.736	10.63 ± 5.263	9.17 ± 8.259	13.02 ± 4.125
Week 48 (n=2,9,14,2,10)	5.75 ± 0.354	6.71 ± 6.065	9.96 ± 4.726	10.50 ± 4.525	12.19 ± 5.096

Week 72 (n=1,8,13,2,10)	13.00	6.89 ± 6.163	8.93 ± 5.416	8.55 ± 3.748	11.80 ± 3.435
Week 96 (n=2,8,13,1,7)	8.70 ± 2.687	6.06 ± 6.283	8.54 ± 4.859	10.20	11.19 ± 4.245
Week 144 (n=1,5,8,2,0)	4.00	7.52 ± 6.222	9.58 ± 6.123	12.45 ± 4.313	
Week 192 (1,2,7,0,0)	3.90	6.45 ± 5.728	6.87 ± 6.145		
Week 240 (1,1,2,0,0)	1.40	1.70	7.85 ± 6.435		

Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Number of Scotomatous Points

Description	Macular sensitivity as assessed by mesopic Microperimetry
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - All treated patients with a valid measurement without a protocol deviation with impact

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	3	9	14	3	11
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Number of Scotomatous Points (units: MP Number of Scotomatous Points)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Week 12 (n=2,9,11,1,10)	6.0 ± 0.00	29.3 ± 13.13	20.4 ± 12.78	44.0	11.9 ± 4.75
Week 24 (n=3,9,10,3,11)	44.3 ± 14.01	30.8 ± 13.15	23.6 ± 12.76	21.0 ± 22.52	12.5 ± 5.87

Week 48 (n=2,9,14,2,10)	40.0 ± 1.41	34.2 ± 15.08	22.0 ± 11.73	16.5 ± 7.78	15.0 ± 7.77
Week 72 (n=1,8,13,2,10)	9.0	35.0 ± 15.07	24.7 ± 12.30	19.5 ± 9.19	15.9 ± 7.37
Week 96 (n=2,8,13,1,7)	26.0 ± 18.38	36.4 ± 16.09	27.5 ± 13.33	17.0	17.0 ± 4.86
Week 144 (n=1,5,8,2,0)	44.0	32.2 ± 16.93	27.6 ± 15.82	17.0 ± 9.90	
Week 192 (1,2,7,0,0)	40.0	37.0 ± 22.63	32.4 ± 18.12		
Week 240 (1,1,2,0,0)	46.0	50.0	33.0 ± 16.97		

Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Percent Fixation Loss (%)

Description	Macular sensitivity as assessed by mesopic Microperimetry
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - All treated patients with a valid measurement without a protocol deviation with impact

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	3	9	14	3	11
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Percent Fixation Loss (%) (units: MP Percent Fixation Loss (%))	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Week 12 (n=2,9,11,1,10)	4.0 ± 5.66	9.8 ± 13.92	6.9 ± 8.69	0.0	5.5 ± 7.11

Week 24 (n=3,9,10,3,11)	0.0 ± 0.00	9.3 ± 17.00	6.4 ± 9.00	0.0 ± 0.00	11.3 ± 8.60
Week 48 (n=2,9,14,2,10)	0.0 ± 0.00	3.8 ± 7.64	10.5 ± 23.45	0.0 ± 0.00	4.6 ± 6.19
Week 72 (n=1,8,13,2,10)	13.0	1.8 ± 4.95	12.0 ± 25.31	4.0 ± 5.66	6.2 ± 8.52
Week 96 (n=2,8,13,1,7)	8.5 ± 12.02	6.5 ± 9.65	10.3 ± 9.06	0.0	7.6 ± 11.07
Week 144 (n=1,5,8,2,0)	0.0	0.0 ± 0.00	4.4 ± 8.11	6.5 ± 9.19	
Week 192 (1,2,7,0,0)	0.0	0.0 ± 0.00	1.7 ± 5.38		
Week 240 (1,1,2,0,0)	0.0	0.0	0.0 ± 0.00		

Change from Baseline Over Time in Square Root of Geographic Atrophy Area Size (mm) via FAF in the Study Eye

Description	Change from baseline in GA size as assessed by fundus autofluorescence
Time Frame	Up to Week 240
Analysis Population Description	Full Analysis Set - for patients with a valid measurement without a protocol deviation with impact

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	21
Change from Baseline Over Time in Square Root of Geographic Atrophy Area Size (mm) via FAF in the Study Eye (units: mm)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**

Week 5 (n=6,10,13,3,20)	0.06 ± 0.081	0.06 ± 0.028	0.06 ± 0.045	0.17 ± 0.147	0.08 ± 0.064
Week 12 (n=6,10,10,3,21)	0.13 ± 0.105	0.09 ± 0.037	0.12 ± 0.061	0.26 ± 0.223	0.15 ± 0.096
Week 24 (n=6,10,13,3,19)	0.20 ± 0.161	0.13 ± 0.053	0.22 ± 0.109	0.37 ± 0.296	0.22 ± 0.111
Week 36 (n=5,5,15,3,19)	0.38 ± 0.232	0.18 ± 0.098	0.25 ± 0.101	0.40 ± 0.310	0.29 ± 0.130
Week 48 (n=5,9,13,3,21)	0.57 ± 0.259	0.23 ± 0.105	0.30 ± 0.118	0.48 ± 0.384	0.35 ± 0.155
Week 72 (n=3,8,14,3,17)	0.57 ± 0.374	0.27 ± 0.090	0.43 ± 0.214	0.57 ± 0.425	0.50 ± 0.247
Week 96 (n=4,8,13,2,18)	0.59 ± 0.424	0.33 ± 0.113	0.54 ± 0.246	0.70 ± 0.822	0.60 ± 0.282
Week 144 (n=2,6,8,3,2)	0.62 ± 0.137	0.42 ± 0.081	0.77 ± 0.329	0.99 ± 0.790	0.98 ± 0.144
Week 192 (n=2,2,5,0,0)	0.89 ± 0.112	0.46 ± 0.042	0.89 ± 0.346		
Week 240 (n=2,0,2,0,0)	1.07 ± 0.216		1.07 ± 0.007		

Rate of successful delivery of Balanced Salt Solution (BSS) or BSS PLUS to the subretinal space (US only)

Description	Rate of successful delivery of GT005 to the subretinal space (US only)
Time Frame	Day 1
Analysis Population Description	All Enrolled Set - All treated US patients with a valid measurement without a protocol deviation with impact

	Total US Patients
Arm/Group Description	Total US Patients
Number of Participants Analyzed [units: participants]	28
Rate of successful delivery of Balanced Salt Solution (BSS) or BSS PLUS to the subretinal space (US only) (units: % (Rate))	
Rate of successful delivery of GT005 by Orbit Subretinal delivery system (SDS) (%)	70.6
Rate of successful delivery of Balanced salt solution BSS/BSS+ (%)	76.5

Rate of successful delivery of GT005 by patient who were intended to be treated using Orbit SDS (%)	85.7

Summary of Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye

Description	Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.
Time Frame	Day 1
Analysis Population Description	Safety Analysis Set - All treated patients

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Summary of Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Subjects with at least one TEAE Related to Surgical Procedure	2 (33.33%)	4 (40%)	9 (60%)	3 (100%)	20 (90.91%)
Eye disorders	2 (33.33%)	4 (40%)	8 (53.33%)	3 (100%)	20 (90.91%)
-Conjunctival haemorrhage	0 (%)	0 (%)	0 (%)	3 (100%)	14 (63.64%)

-Cataract	1 (16.67%)	3 (30%)	7 (46.67%)	0 (%)	0 (%)
-Retinal pigmentation	0 (%)	2 (20%)	2 (13.33%)	0 (%)	6 (27.27%)
-Retinal haemorrhage	0 (%)	1 (10%)	1 (6.67%)	3 (100%)	3 (13.64%)
-Anterior chamber cell	0 (%)	0 (%)	1 (6.67%)	1 (33.33%)	3 (13.64%)
-Conjunctival hyperaemia	0 (%)	0 (%)	1 (6.67%)	0 (%)	2 (9.09%)
-Retinal tear	0 (%)	0 (%)	0 (%)	0 (%)	3 (13.64%)
-Vitreous floaters	0 (%)	0 (%)	1 (6.67%)	1 (33.33%)	0 (%)
-Choroidal haemorrhage	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Choroidal neovascularisation	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Corneal oedema	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Dry eye	1 (16.67%)	0 (%)	0 (%)	0 (%)	0 (%)
-Eye discharge	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)
-Eye pain	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Eye pruritus	0 (%)	1 (10%)	0 (%)	0 (%)	0 (%)
-Foreign body sensation in eyes	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Iridocyclitis	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)

-Keratitis	0 (%)	0 (%)	0 (%)	1 (33.33%)	0 (%)
-Ocular discomfort	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Periorbital oedema	1 (16.67%)	0 (%)	0 (%)	0 (%)	0 (%)
Injury, poisoning and procedural complications	0 (%)	0 (%)	2 (13.33%)	0 (%)	3 (13.64%)
-Corneal abrasion	0 (%)	0 (%)	1 (6.67%)	0 (%)	1 (4.55%)
-Post procedural discomfort	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Procedural pain	0 (%)	0 (%)	0 (%)	0 (%)	1 (4.55%)
-Suture related complication	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
Investigations	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)
-Intraocular pressure increased	0 (%)	0 (%)	1 (6.67%)	0 (%)	0 (%)

Summary of Non-Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure

Description	Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.
Time Frame	Day 1
Analysis Population Description	Safety Analysis Set - All treated patients

	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Summary of Non-Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)

Summary of Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye

Description	Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.
Time Frame	Day 1
Analysis Population Description	Safety Analysis Set - All treated patients

	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System

Number of Participants Analyzed [units: participants]	6	10	15	3	22
Summary of Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)

Summary of Non-Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure

Description: Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

Time Frame: Day 1

Analysis Population Description: Safety Analysis Set - All treated patients

	GT005 2E10 vg via Transvitreal Procedure	**GT005 5E10 vg via Transvitreal Procedure**	**GT005 2E11 vg via Transvitreal Procedure**	**GT005 5E10 vg with Orbit Subretinal Delivery System**	**GT005 2E11 vg with Orbit Subretinal Delivery System**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System
Number of Participants Analyzed [units: participants]	6	10	15	3	22
Summary of Non-Ocular Serious Treatment-Emergent Adverse Events Related to Surgical	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**

Procedure (units: Participants)					
	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)

Other Pre-Specified Outcome Result(s)

No data identified.

Post-Hoc Outcome Result(s)

No data identified.

Safety Results

Time Frame	Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Source Vocabulary for Table Default	MedDRA (26.0)
Collection Approach for Table Default	Systematic Assessment

All-Cause Mortality

	GT005 2E10 vg via Transvitreal	GT005 5E10 vg via Transvitreal	GT005 2E11 vg via Transvitreal	GT005 5E10 vg with Orbit Subretinal	GT005 2E11 vg with Orbit Subretinal	Overall N = 56

	Procedure N = 6	Procedure N = 10	Procedure N = 15	Delivery System N = 3	Delivery System N = 22	
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System	Overall
Total Number Affected	1	3	0	0	0	4
Total Number At Risk	6	10	15	3	22	56

Serious Adverse Events

Time Frame	Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Source Vocabulary for Table Default	MedDRA (26.0)
Collection Approach for Table Default	Systematic Assessment

	GT005 2E10 vg via Transvitreal Procedure N = 6	GT005 5E10 vg via Transvitreal Procedure N = 10	GT005 2E11 vg via Transvitreal Procedure N = 15	GT005 5E10 vg with Orbit Subretinal Delivery System N = 3	GT005 2E11 vg with Orbit Subretinal Delivery System N = 22	Overall N = 56
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System	Overall

Total # Affected by any Serious Adverse Event	2	6	4	0	5	17
Total # at Risk by any Serious Adverse Event	6	10	15	3	22	56
Cardiac disorders						
Acute myocardial infarction	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Atrial fibrillation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Bradycardia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Cardiac failure congestive	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Pericardial effusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Ventricular tachycardia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Gastrointestinal disorders						
Haematemesis	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Inguinal hernia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Hepatobiliary disorders						
Cholangitis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Infections and infestations						
Cellulitis	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
COVID-19	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Lower respiratory tract infection	1 (16.67%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Pneumonia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Pneumonia aspiration	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Septic shock	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Staphylococcal infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)

Injury, poisoning and procedural complications						
Fall	0 (0.00%)	0 (0.00%)	2 (13.33%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Femoral neck fracture	1 (16.67%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Joint dislocation	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Rib fracture	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Subdural haemorrhage	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)						
Breast cancer	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Lung adenocarcinoma	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Lymphatic system neoplasm	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Oesophageal carcinoma	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Nervous system disorders						
Cerebral haemorrhage	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Cerebrovascular accident	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Presyncope	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Syncope	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Respiratory, thoracic and mediastinal disorders						
Pleural effusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Pneumothorax spontaneous	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Vascular disorders						
Deep vein thrombosis	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Peripheral artery aneurysm	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)

Other (Not Including Serious) Adverse Events

Time Frame	Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Source Vocabulary for Table Default	MedDRA (26.0)
Collection Approach for Table Default	Systematic Assessment
Frequent Event Reporting Threshold	0%

	GT005 2E10 vg via Transvitreal Procedure N = 6	**GT005 5E10 vg via Transvitreal Procedure N = 10**	**GT005 2E11 vg via Transvitreal Procedure N = 15**	**GT005 5E10 vg with Orbit Subretinal Delivery System N = 3**	**GT005 2E11 vg with Orbit Subretinal Delivery System N = 22**	**Overall N = 56**
Arm/Group Description	GT005 2E10 vg via Transvitreal Procedure	GT005 5E10 vg via Transvitreal Procedure	GT005 2E11 vg via Transvitreal Procedure	GT005 5E10 vg with Orbit Subretinal Delivery System	GT005 2E11 vg with Orbit Subretinal Delivery System	Overall
Total # Affected by any Other Adverse Event	4	10	15	3	22	54
Total # at Risk by any Other Adverse Event	6	10	15	3	22	56

Blood and lymphatic system disorders						
Anaemia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Iron deficiency anaemia	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Neutropenia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Cardiac disorders						
Angina pectoris	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Aortic valve incompetence	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Arrhythmia	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Atrial fibrillation	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Bradycardia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Diastolic dysfunction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Ventricular tachycardia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Congenital, familial and genetic disorders						
Corneal dystrophy - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Corneal dystrophy - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Ear and labyrinth disorders						
Ear pruritus	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	1 (1.79%)
Vertigo	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Endocrine disorders						
Goitre	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Hypothyroidism	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Eye disorders						

Anterior chamber cell - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	1 (33.33%)	3 (13.64%)	5 (8.93%)
Blepharitis - Fellow eye	0 (0.00%)	3 (30.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	3 (5.36%)
Blepharitis - Study eye	0 (0.00%)	3 (30.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	3 (5.36%)
Cataract - Fellow eye	1 (16.67%)	1 (10.00%)	2 (13.33%)	0 (0.00%)	2 (9.09%)	6 (10.71%)
Cataract - Study eye	1 (16.67%)	3 (30.00%)	7 (46.67%)	0 (0.00%)	2 (9.09%)	13 (23.21%)
Central vision loss - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Chalazion - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	1 (1.79%)
Charles Bonnet syndrome - Fellow eye	1 (16.67%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Charles Bonnet syndrome - Study eye	1 (16.67%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Choroidal haemorrhage - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Choroidal neovascularisation - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Choroidal neovascularisation - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Conjunctival deposit - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Conjunctival haemorrhage - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	3 (100.00%)	15 (68.18%)	18 (32.14%)
Conjunctival hyperaemia - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	2 (9.09%)	3 (5.36%)
Corneal oedema - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Dacryostenosis acquired - Study eye	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Diplopia - Fellow eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Diplopia - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Dry eye - Fellow eye	0 (0.00%)	2 (20.00%)	2 (13.33%)	0 (0.00%)	1 (4.55%)	5 (8.93%)

Dry eye - Study eye	1 (16.67%)	2 (20.00%)	2 (13.33%)	0 (0.00%)	2 (9.09%)	7 (12.50%)
Eye discharge - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	1 (1.79%)
Eye pain - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Eye pain - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Eye pruritus - Study eye	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Eyelid irritation - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	1 (1.79%)
Eyelid ptosis - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Eyelid ptosis - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Foreign body sensation in eyes - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Glaucoma - Fellow eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Glaucoma - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Iridocyclitis - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Keratitis - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	1 (1.79%)
Macular hole - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Neovascular age-related macular degeneration - Fellow eye	0 (0.00%)	0 (0.00%)	2 (13.33%)	1 (33.33%)	0 (0.00%)	3 (5.36%)
Neovascular age-related macular degeneration - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	2 (9.09%)	3 (5.36%)
Ocular discomfort - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Ocular hypertension - Fellow eye	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Ocular hypertension - Study eye	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Optic disc haemorrhage - Fellow eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)

Optic disc haemorrhage - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Periorbital oedema - Study eye	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Posterior capsule opacification - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Posterior capsule opacification - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Retinal aneurysm rupture - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Retinal depigmentation - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Retinal haemorrhage - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	2 (9.09%)	3 (5.36%)
Retinal haemorrhage - Study eye	0 (0.00%)	2 (20.00%)	1 (6.67%)	3 (100.00%)	5 (22.73%)	11 (19.64%)
Retinal pigmentation - Fellow eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (9.09%)	2 (3.57%)
Retinal pigmentation - Study eye	0 (0.00%)	4 (40.00%)	10 (66.67%)	0 (0.00%)	8 (36.36%)	22 (39.29%)
Retinal tear - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	4 (18.18%)	4 (7.14%)
Vision blurred - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Vision blurred - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Visual acuity reduced - Fellow eye	0 (0.00%)	3 (30.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	4 (7.14%)
Visual acuity reduced - Study eye	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Visual field defect - Fellow eye	0 (0.00%)	0 (0.00%)	2 (13.33%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Visual field defect - Study eye	0 (0.00%)	0 (0.00%)	3 (20.00%)	0 (0.00%)	0 (0.00%)	3 (5.36%)
Visual impairment - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Visual impairment - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)

Vitreous floaters - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	1 (33.33%)	0 (0.00%)	2 (3.57%)
Gastrointestinal disorders						
Constipation	0 (0.00%)	3 (30.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	4 (7.14%)
Diarrhoea	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Dysphagia	0 (0.00%)	2 (20.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	3 (5.36%)
Gastritis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Gastrooesophageal reflux disease	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	2 (9.09%)	3 (5.36%)
Hiatus hernia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Intestinal polyp	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Intra-abdominal haematoma	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Large intestine polyp	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Nausea	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Oesophageal perforation	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Oesophageal stenosis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Vomiting	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
General disorders and administration site conditions						
Adverse drug reaction	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Chest pain	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Fatigue	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hernia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Oedema	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Oedema peripheral	1 (16.67%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	3 (5.36%)
Pain	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Polyp	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)

Vessel puncture site bruise	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hepatobiliary disorders						
Cholelithiasis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hepatic cyst	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Immune system disorders						
Drug hypersensitivity	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Infections and infestations						
Bronchitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Cellulitis	1 (16.67%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	3 (5.36%)
Conjunctivitis - Fellow eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Conjunctivitis - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (9.09%)	2 (3.57%)
Conjunctivitis bacterial - Fellow eye	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Conjunctivitis bacterial - Study eye	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Conjunctivitis viral - Fellow eye	0 (0.00%)	2 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Conjunctivitis viral - Study eye	0 (0.00%)	2 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
COVID-19	0 (0.00%)	2 (20.00%)	2 (13.33%)	0 (0.00%)	5 (22.73%)	9 (16.07%)
Cystitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Diverticulitis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Ear infection	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Fungal infection	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Fungal skin infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Gastroenteritis bacterial	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Herpes zoster	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)

Hordeolum - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Influenza	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Lower respiratory tract infection	0 (0.00%)	3 (30.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	4 (7.14%)
Nasopharyngitis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Oral candidiasis	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Pharyngitis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Pneumonia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Staphylococcal skin infection	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Upper respiratory tract infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Urinary tract infection	0 (0.00%)	2 (20.00%)	2 (13.33%)	0 (0.00%)	0 (0.00%)	4 (7.14%)
Viral sinusitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Vulvovaginal mycotic infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Injury, poisoning and procedural complications						
Arthropod bite	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Contusion	1 (16.67%)	2 (20.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	4 (7.14%)
Corneal abrasion - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Eye contusion - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Fall	3 (50.00%)	2 (20.00%)	2 (13.33%)	0 (0.00%)	0 (0.00%)	7 (12.50%)
Foreign body in eye - Fellow eye	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Head injury	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Lumbar vertebral fracture	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Pelvic fracture	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Post procedural discomfort - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)

Procedural pain - Study eye	0 (0.00%)	0 (0.00%)	3 (20.00%)	0 (0.00%)	1 (4.55%)	4 (7.14%)
Scrotal haematoma	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Skin injury	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Skin laceration	2 (33.33%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	3 (5.36%)
Skin wound	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Suture related complication - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Thermal burn	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Investigations						
Alanine aminotransferase increased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood albumin decreased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood alkaline phosphatase increased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood bicarbonate decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Blood bilirubin increased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood cholesterol increased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood creatine phosphokinase increased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood folate decreased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood glucose increased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood lactate dehydrogenase increased	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood potassium increased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Blood pressure increased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Coronavirus test positive	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
C-reactive protein increased	0 (0.00%)	1 (10.00%)	1 (6.67%)	1 (33.33%)	0 (0.00%)	3 (5.36%)

Gamma-glutamyltransferase increased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Haemoglobin decreased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Heart rate irregular	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Intraocular pressure increased - Fellow eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	1 (33.33%)	0 (0.00%)	2 (3.57%)
Intraocular pressure increased - Study eye	0 (0.00%)	0 (0.00%)	1 (6.67%)	1 (33.33%)	1 (4.55%)	3 (5.36%)
Lipids increased	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Liver function test abnormal	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Liver function test increased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Neutrophil count increased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Protein C increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Protein total decreased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Weight decreased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
White blood cell count increased	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Metabolism and nutrition disorders						
Failure to thrive	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hypercalcaemia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hyperglycaemia	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hyperlipidaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Hypervolaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Hypokalaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Iron deficiency	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Type 2 diabetes mellitus	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Vitamin B12 deficiency	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)

Vitamin D deficiency	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Musculoskeletal and connective tissue disorders						
Arthralgia	1 (16.67%)	1 (10.00%)	1 (6.67%)	1 (33.33%)	2 (9.09%)	6 (10.71%)
Back pain	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Exostosis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Groin pain	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Intervertebral disc degeneration	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Joint swelling	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Muscle spasms	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Myalgia	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Osteoarthritis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Pain in extremity	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Pathological fracture	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Spinal stenosis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Tendonitis	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Trigger finger	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)						
Adenoma benign	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Basal cell carcinoma	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Benign neoplasm	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Keratoacanthoma	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Sweat gland tumour	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Nervous system disorders						

Aphasia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Carotid artery stenosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Cerebral artery thrombosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Cluster headache	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Dementia	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Dizziness	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Headache	0 (0.00%)	1 (10.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	2 (3.57%)
Meralgia paraesthetica	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Ophthalmic migraine - Fellow eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	1 (1.79%)
Ophthalmic migraine - Study eye	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (33.33%)	0 (0.00%)	1 (1.79%)
Post herpetic neuralgia	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Transient ischaemic attack	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Vertebral artery occlusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Psychiatric disorders						
Anxiety	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Confusional state	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hallucination	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Renal and urinary disorders						
Acute kidney injury	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Chronic kidney disease	0 (0.00%)	0 (0.00%)	3 (20.00%)	0 (0.00%)	0 (0.00%)	3 (5.36%)
Haematuria	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Nephrolithiasis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Reproductive system and breast disorders						

Breast mass	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Respiratory, thoracic and mediastinal disorders						
Acute respiratory failure	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Asthma	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	2 (3.57%)
Cough	1 (16.67%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	1 (4.55%)	3 (5.36%)
Dyspnoea	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Haemoptysis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Interstitial lung disease	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Oropharyngeal pain	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Sinus congestion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Upper-airway cough syndrome	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Skin and subcutaneous tissue disorders						
Decubitus ulcer	0 (0.00%)	2 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Dermatitis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Dry skin	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Haemosiderin stain	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hyperkeratosis	1 (16.67%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Night sweats	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Panniculitis	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Precancerous skin lesion	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Rosacea	0 (0.00%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Skin lesion	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Skin ulcer	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Stasis dermatitis	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)

Vascular disorders						
Aortic stenosis	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Hypertension	2 (33.33%)	0 (0.00%)	1 (6.67%)	0 (0.00%)	2 (9.09%)	5 (8.93%)
Hypertensive emergency	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Hypotension	0 (0.00%)	1 (10.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Lymphoedema	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Orthostatic hypotension	0 (0.00%)	1 (10.00%)	1 (6.67%)	0 (0.00%)	0 (0.00%)	2 (3.57%)
Poor peripheral circulation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (4.55%)	1 (1.79%)
Vein disorder	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)
Venous hypertension	1 (16.67%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (1.79%)

Other Relevant Findings:

Conclusion:

Safety assessments indicated that GT005 was generally well tolerated.

As expected in early development phase studies, participants were not randomized, and this contributed to enrolling participants with more advance disease state in cohort 1 through 4.

The study was terminated early following recommendation by DMC that overall benefit risk ratio did not support continuation of the current development program as planned.

Date of Clinical Trial Report

18-Oct-2024